Specialist pharmaceutical maker Shield Therapeutics (STX) delivered investors more good news with the potential approval of ACCRUFeR in China. The firm’s local partner ASK has filed for marketing authorisation and expects approval this quarter. Share price: £11.10 (+1%) PE: n/a Market cap: £118m Yield: n/a APPROVAL THIS QUARTER ACCRUFeR is an oral therapy for adults … Continue reading Shield Therapeutics delivers more good news